课题基金 / 基金详情

Characterization of tumor-infiltrating B-cells in cutaneous T-cell lymphoma

Characterization of tumor-infiltrating B-cells in cutaneous T-cell lymphoma
皮肤 T 细胞淋巴瘤中肿瘤浸润 B 细胞的特征
批准号:
391587558
负责人:
Professor Dr. Michael von Bergwelt-Baildon
金额:
$0.0万
依托单位国家:
德国
项目类别:
Research Grants
财政年份:
2018
资助国家:
德国
项目状态:
已结题
起止时间:
2017-12-31 至 2022-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The overall aim of this project is the characterization of tumor-infiltrating B-cells in cutaneous T-cell lymphoma.B-cells are conventionally regarded as antibody-producing cells of the adaptive immune response. However, it has been known for some years that B-cells can also act as professional antigen-presenting cells and immunoregulatory cells and, as such, can contribute significantly to the pathogenesis of autoimmune diseases and cancer.Cutaneous T-cell lymphomas (CTCL) are a highly intersting cancer entity from a tumor-immunological viewpoint because they are immunogenic and can be monitored clinically and serially biopsied. In early stages, CTCL hardly affect the life expectancy of the affected individuals. However, in some cases and associated with certain CTCL subtypes, a rapid, aggressive course can occur already in the early phase of the disease, for which the reasons are not fully understood. In close cooperation with our dermatological colleagues (Dr. Schlaak, Prof. Stadler), we have in our preliminary work observed that the tumor tissues of aggressive and advanced CTCL show strong B-cell infiltrates, which correlated with por survival. In addition, we observed that local B-cell depletion by the CD20 antibody rituximab in a patient with refractory CTCL and demonstrably strong B-cell infiltrate resulted in a complete and sustained local tumor remission. However, the precise characteristics of CTCL-associated B-cells and their function are still largely unknown. In this project, we therefore aim to characterize CTCL-infiltrating B-cells in detail using phenotypical and functional ex vivo and in vivo (mouse) experiments. The results could help develop a novel immunotherapeutic treatment option for advanced and standard therapy refractory CTCL cases, which does not directly act on the malignant cells but rather shapes the tumor immune environment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
蛋白精氨酸甲基化转移酶PRMT5调控PPARG促进巨噬细胞M2极化及其在肿瘤中作用的机制研究
  • 批准号:
    82371738
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    郑英霞
  • 依托单位:
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
  • 批准号:
    82304565
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    李瑾
  • 依托单位:
放疗通过激活GSDMD诱发细胞焦亡促进肿瘤再增殖的机制研究及干预策略探讨
  • 批准号:
    82373299
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    程进
  • 依托单位:
基于“Healthy-NAT-Tumor”三维度的食管鳞癌蛋白组学数据挖掘及其临床意义研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    刘伟
  • 依托单位: